Damora Therapeutics, Inc. (DMRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Damora Therapeutics, Inc. (DMRA) has a cash flow conversion efficiency ratio of -0.042x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.87 Million) by net assets ($516.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DMRA stock market capitalisation for the company's overall valuation and market capitalisation.
Damora Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Damora Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View DMRA stock price and chart for real-time trading data and today's change.
Damora Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Damora Therapeutics, Inc. ranked by their cash flow conversion efficiency. Review Damora Therapeutics, Inc. free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Laurentian Bank Of Canada
TO:LB
|
0.171x |
|
Westamerica Bancorporation
NASDAQ:WABC
|
0.032x |
|
ACV Auctions Inc.
NYSE:ACVA
|
0.178x |
|
Shanghai Weaver Network Co Ltd
SHG:603039
|
0.046x |
|
Hubei Wanrun New Energy Technology Co. Ltd. A
SHG:688275
|
N/A |
|
Cascades Inc.
TO:CAS
|
0.064x |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
1.808x |
|
Loma Negra Compania Industrial Argentina SA ADR
NYSE:LOMA
|
0.016x |
Annual Cash Flow Conversion Efficiency for Damora Therapeutics, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Damora Therapeutics, Inc. from 2018 to 2025. Also see DMRA total asset value for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $240.38 Million | $-6.73 Million | -0.028x | +97.83% |
| 2024-12-31 | $14.47 Million | $-18.62 Million | -1.287x | -12.72% |
| 2023-12-31 | $32.33 Million | $-36.91 Million | -1.142x | -64.22% |
| 2022-12-31 | $61.75 Million | $-42.93 Million | -0.695x | -55.80% |
| 2021-12-31 | $117.22 Million | $-52.31 Million | -0.446x | -93.30% |
| 2020-12-31 | $165.49 Million | $-38.20 Million | -0.231x | +42.10% |
| 2019-12-31 | $48.47 Million | $-19.33 Million | -0.399x | +10.71% |
| 2018-12-31 | $30.66 Million | $-13.69 Million | -0.447x | -- |
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to u… Read more